PMID- 25378949
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141107
LR  - 20220316
IS  - 1179-1314 (Print)
IS  - 1179-1314 (Electronic)
IS  - 1179-1314 (Linking)
VI  - 6
DP  - 2014
TI  - Assessment of HER2 testing patterns, HER2+ disease, and the utilization of 
      HER2-directed therapy in early breast cancer.
PG  - 169-77
LID - 10.2147/BCTT.S69416 [doi]
AB  - CONTEXT: Determining human epidermal growth factor receptor 2 (HER2) status is 
      critical for the management of early-stage breast cancer (ESBC). An understanding 
      of HER2 testing practices can provide insight into how test results influence the 
      use of HER2-directed therapy. OBJECTIVE: To assess HER2 testing, HER2+ disease, 
      and HER2-directed therapy in ESBC at the Huntsman Cancer Institute before and 
      after the 2007 American Society of Clinical Oncology and College of American 
      Pathologist (ASCO/CAP) guidelines on HER2 testing were published. METHODS: 
      Patients were identified from an institutional tumor registry. HER2 testing 
      patterns and results were examined using a chart review of pathology and clinical 
      notes. Patient characteristics, HER2+ rate, and trastuzumab use were evaluated 
      descriptively. Discordance rate with reflex testing (immunohistochemistry [IHC]2+ 
      retested by fluorescence in situ hybridization [FISH]) was also evaluated. 
      RESULTS: A total of 1,459 women were included (mean age: 57 years). The rate of 
      HER2+ disease was 17% (number [N] =245). The discordance rate between IHC2+ and 
      FISH was 10%. After the 2007 ASCO/CAP guidelines, fewer tumors were classified as 
      IHC3+ (16% post- versus 21.9% pre-2007), more tumors were characterized as IHC2+ 
      (26.4% post- versus 20.7% pre-2007), and the overall HER2+ rate was decreased 
      (18.7% versus 21.9%), but this was not statistically significant (P=0.519). Most 
      patients with HER2+ ESBC received HER2-targeted therapy (N=185). CONCLUSION: The 
      HER2+ rate was 17% and within the range of the reported rates in the literature. 
      Reflex testing identified additional HER2+ tumors by approximately 10%, and 
      should be considered a potential quality indicator. ASCO/CAP HER2 testing 
      guidelines in 2007 appeared to impact the interpretation and classification of 
      HER2+ tumors.
FAU - Stenehjem, David D
AU  - Stenehjem DD
AD  - Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University 
      of Utah, Salt Lake City, UT, USA ; Huntsman Cancer Institute, Salt Lake City, UT, 
      USA.
FAU - Yoo, Minkyoung
AU  - Yoo M
AD  - Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University 
      of Utah, Salt Lake City, UT, USA.
FAU - Unni, Sudhir K
AU  - Unni SK
AD  - Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University 
      of Utah, Salt Lake City, UT, USA.
FAU - Singhal, Mukul
AU  - Singhal M
AD  - Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University 
      of Utah, Salt Lake City, UT, USA.
FAU - Bauer, Hillevi
AU  - Bauer H
AD  - Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University 
      of Utah, Salt Lake City, UT, USA.
FAU - Saverno, Kim
AU  - Saverno K
AD  - Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University 
      of Utah, Salt Lake City, UT, USA.
FAU - Quah, Cheng
AU  - Quah C
AD  - Genentech, Inc., South San Francisco, CA, USA.
FAU - Masaquel, Anthony
AU  - Masaquel A
AD  - Genentech, Inc., South San Francisco, CA, USA.
FAU - Brixner, Diana I
AU  - Brixner DI
AD  - Pharmacotherapy Outcomes Research Center (PORC), College of Pharmacy, University 
      of Utah, Salt Lake City, UT, USA ; Program in Personalized Health Care, 
      University of Utah, Salt Lake City, UT, USA.
LA  - eng
PT  - Journal Article
DEP - 20141029
PL  - New Zealand
TA  - Breast Cancer (Dove Med Press)
JT  - Breast cancer (Dove Medical Press)
JID - 101591856
PMC - PMC4218922
OTO - NOTNLM
OT  - FISH
OT  - HER2
OT  - HER2-targeted therapy
OT  - early-stage breast cancer
OT  - human epidermal growth factor receptor 2
OT  - immunohistochemistry
EDAT- 2014/11/08 06:00
MHDA- 2014/11/08 06:01
PMCR- 2014/10/29
CRDT- 2014/11/08 06:00
PHST- 2014/11/08 06:00 [entrez]
PHST- 2014/11/08 06:00 [pubmed]
PHST- 2014/11/08 06:01 [medline]
PHST- 2014/10/29 00:00 [pmc-release]
AID - bctt-6-169 [pii]
AID - 10.2147/BCTT.S69416 [doi]
PST - epublish
SO  - Breast Cancer (Dove Med Press). 2014 Oct 29;6:169-77. doi: 10.2147/BCTT.S69416. 
      eCollection 2014.